Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand.
Antibody-dependent cell-mediated cytotoxicity (ADCC) was assessed in volunteers participating in an ALVAC-HIV (vCP1521)/AIDSVAX B/E gp120 prime-boost vaccine trial in Thailand. ADCC activity was measured using chromium release from gp120 subtype B- and CRF01_AE-coated targets in 95 vaccinees and 28 placebo recipients. There was a significant difference in the magnitude of the ADCC response to both targets between vaccinees and placebo recipients. The frequency of responders to subtype B and to CRF01_AE was 96% and 84% in the vaccine group versus 11% and 7% in the placebo group. The results demonstrate that this HIV vaccine is a potent inducer of ADCC activity and may be an additional protection of this prime-boost vaccine in preventing HIV disease.
Karnasuta
Chitraporn
C
Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. chitrapornk@afrims.org
Paris
Robert M
RM
Cox
Josephine H
JH
Nitayaphan
Sorachai
S
Pitisuttithum
Punnee
P
Thongcharoen
Prasert
P
Brown
Arthur E
AE
Gurunathan
Sanjay
S
Tartaglia
James
J
Heyward
William L
WL
McNeil
John G
JG
Birx
Deborah L
DL
de Souza
Mark S
MS
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000328:Adult; D002860:Chromium Radioisotopes / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D004311:Double-Blind Method; D005260:Female; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D007111:Immunity, Cellular; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D013785:Thailand; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
D016915:AIDS Vaccines; C112734:AIDSVAX; D002860:Chromium Radioisotopes; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D022223:Vaccines, Subunit